| 產品編號 | bs-7555R |
| 英文名稱 | phospho-EPH A3+A4+A5 ( Tyr779) Rabbit pAb |
| 中文名稱 | 磷酸化內皮細胞受體蛋白酪氨酸激酶A3+A4+A5抗體 |
| 別 名 | EPH A3+A4+A5(phospho Y779+Y779+Y833); EPH A3+A4+A5(phospho Y779); p-EPH A3+A4+A5(phospho Y779); CEK7; EHK 1; EHK1; EK4; EK7; EK8; EPH homology kinase 1; EPH like kinase 4; EPH like kinase 7; EPH like kinase 8; Eph like tyrosine kinase 1; EPH receptor A3; |
| 產品類型 | 磷酸化抗體 |
| 研究領域 | 細胞生物 神經生物學 信號轉導 激酶和磷酸酶 細胞膜受體 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Mouse,Rat (predicted: Rabbit,Pig,Cow,Chicken,Dog,Horse) |
| 產品應用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 108 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞膜 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human around the phosphorylation site of EPH 3 Tyr779: AA(p-Y)TT |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
EphA3 is a member of the Ephrin (Eph) family. The Ephrins and Eph-related receptors comprise the largest subfamily of receptor protein-tyrosine kinases and have been implicated in mediating developmental events, especially in the nervous system and in erythropoiesis. Based on their structures and sequence relationships, ephrins are divided into the Ephrin A (EphA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the Ephrin B (EphB) class, which are transmembrane proteins. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. Function: Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5. Upon activation by EFNA5 regulates cell-cell adhesion, cytoskeletal organization and cell migration. Plays a role in cardiac cells migration and differentiation and regulates the formation of the atrioventricular canal and septum during development probably through activation by EFNA1. Involved in the retinotectal mapping of neurons. May also control the segregation but not the guidance of motor and sensory axons during neuromuscular circuit development. Subunit: Heterotetramer upon binding of the ligand. The heterotetramer is composed of an ephrin dimer and a receptor dimer. Oligomerization is probably required to induce biological responses. Forms a ternary EFNA5-EPHA3-ADAM10 complex mediating EFNA5 extracellular domain shedding by ADAM10 which regulates the EFNA5-EPHA3 complex internalization and function. Interacts with NCK1 (via SH2 domain); mediates EFNA5-EPHA3 signaling (By similarity). Interacts (phosphorylated) with PTPN1; dephosphorylates EPHA3 and may regulate its trafficking and function. Interacts (phosphorylated) with CRK; mediates EFNA5-EPHA3 signaling through RHOA GTPase activation. Subcellular Location: Isoform 1: Cell membrane; Single-pass type I membrane protein. Isoform 2: Secreted. Tissue Specificity: Widely expressed. Highest level in placenta. Post-translational modifications: Autophosphorylates upon activation by EFNA5. Phosphorylation on Tyr-602 mediates interaction with NCK1. Dephosphorylated by PTPN1. DISEASE: Defects in EPHA3 may be a cause of colorectal cancer (CRC) [MIM:114500]. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily. Contains 1 Eph LBD (Eph ligand-binding) domain. Contains 2 fibronectin type-III domains. Contains 1 protein kinase domain. Contains 1 SAM (sterile alpha motif) domain. SWISS: P54764 Gene ID: 2044 Database links: Entrez Gene: 2042 Human Entrez Gene: 2043 Human Entrez Gene: 2044 Human Entrez Gene: 13837 Mouse Entrez Gene: 13838 Mouse Entrez Gene: 13839 Mouse Omim: 179611 Human Omim: 600004 Human Omim: 602188 Human SwissProt: P29320 Human SwissProt: P54756 Human SwissProt: P54764 Human SwissProt: P29319 Mouse SwissProt: Q03137 Mouse SwissProt: Q60629 Mouse Unigene: 123642 Human Unigene: 371218 Human Unigene: 654492 Human Unigene: 137991 Mouse Unigene: 1977 Mouse Unigene: 400747 Mouse Unigene: 10713 Rat Unigene: 24569 Rat Unigene: 6202 Rat |
| 產品圖片 |
Sample:
Lane 1: Human HeLa cell lysates
Lane 2: Human HeLa（Serum-starve cells overnight， treat with the freshly made Pervanadate for 20min at 37°C.）
Primary: Anti-phospho-EPH A3+A4+A5 ( Tyr779) (bs-7555R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 108 kDa
Observed band size: 105 kDa
Paraformaldehyde-fixed, paraffin embedded (Rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-EPH A3+A4+A5 (Tyr779)) Polyclonal Antibody, Unconjugated (bs-7555R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-EPH A3+A4+A5 (Tyr779)) Polyclonal Antibody, Unconjugated (bs-7555R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
